A new study by the American Stroke Association found that the risk of stroke in adults with COVID-19 between the ages of 65 to 74 was highest the first three days after diagnosis. Additionally, investigators at the National Institutes of Allergy and Infectious Diseases’ Vaccine Research Center ran tests on primates and found that updating COVID-19 vaccines to focus on the Omicron variant may not provide much benefit.

The U.S. Food and Drug Administration on December 8 authorized the use of AstraZeneca’s antibody cocktail to prevent Covid-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

AstraZeneca is examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on the company’s vaccine and antibody cocktail, and is hopeful that the combination drug would retain efficacy.

AstraZeneca on Thursday cemented the company’s lead in bringing a preventative Covid-19 shot to market, saying its antibody cocktail offered 83 percent protection over six months, another possible weapon in the fight against the pandemic.

The U.S. Food and Drug Administration agreed to place Regeneron Pharmaceuticals Inc.’s Biologics License Application (BLA) for the Covid-19 drug REGEN-COV under priority review with a target action date of April 13, 2022.

In October 2020, the government recommended against kids going trick-or-treating for Halloween out of fear of Covid-19 spread. For Halloween 2021, kids have been given the green light to knock on doors.

AstraZeneca’s antibody cocktail against Covid-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.

The UK drug regulator approved an antibody cocktail developed by Regeneron and Roche to prevent and treat Covid-19, as the nation battles rising hospitalizations due to the more infectious Delta variant.

The U.S. Food and Drug Administration expanded the emergency use authorization of Regeneron Pharmaceuticals Inc.’s Covid-19 antibody cocktail, enabling the combo therapy’s use as a preventive treatment for the illness in certain people.